圣诺生物：预计2025年前三季度净利润约1.14亿元~1.4亿元，同比增加100.53%~145.1%

Core Viewpoint - Shengnuo Biotech (SH 688117) expects a significant increase in net profit for the first three quarters of 2025, projecting a profit of approximately 114 million to 140 million yuan, representing a year-on-year increase of 100.53% to 145.1% [1] Financial Performance - The projected net profit increase of 57.25 million to 82.63 million yuan is attributed to stable development in the company's main business and growing demand for its peptide raw materials [1] - The company's revenue composition for 2024 is expected to be 98.91% from the pharmaceutical manufacturing sector and 1.09% from other businesses [1] Market Position - Shengnuo Biotech maintains strong market competitiveness and sustained profitability due to the substantial growth in its overall performance [1]